{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T16:08:25Z","timestamp":1756310905415,"version":"3.40.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1245\/s10434-025-17041-1","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T18:44:23Z","timestamp":1739990663000},"page":"3975-3983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Assessment of Locoregional Management of the Axilla in Node-Positive Breast Cancer After Neoadjuvant Chemotherapy"],"prefix":"10.1245","volume":"32","author":[{"given":"Katherine","family":"Fleshner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Isherwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akaya","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Hanniman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Bouchard-Fortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May Lynn","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"10","key":"17041_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918\u201326. https:\/\/doi.org\/10.1001\/jama.2017.11470.","journal-title":"JAMA."},{"issue":"12","key":"17041_CR2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7.","journal-title":"Lancet Oncol."},{"key":"17041_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313487","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Tvedskov TF, Ryd\u00e9n L, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2313487.","journal-title":"N Engl J Med."},{"issue":"1","key":"17041_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1200\/JCO.1999.17.1.143","volume":"17","author":"TF Hack","year":"1999","unstructured":"Hack TF, Cohen L, Katz J, Robson LS, Goss P. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol. 1999;17(1):143\u2013143. https:\/\/doi.org\/10.1200\/JCO.1999.17.1.143.","journal-title":"J Clin Oncol."},{"key":"17041_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1477-7819-12-67","volume":"12","author":"EWS Soares","year":"2014","unstructured":"Soares EWS, Nagai HM, Bredt LC, da Cunha AD, Andrade RJ, Soares GVS. Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients. World J Surg Oncol. 2014;12:67. https:\/\/doi.org\/10.1186\/1477-7819-12-67.","journal-title":"World J Surg Oncol."},{"issue":"14","key":"17041_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA."},{"issue":"7","key":"17041_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9.","journal-title":"Lancet Oncol."},{"issue":"3","key":"17041_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(3):258\u201364. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"27","key":"17041_CR9","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.21.00934","volume":"39","author":"M Brackstone","year":"2021","unstructured":"Brackstone M, Baldassarre FG, Perera FE, et al. Management of the axilla in early-stage breast cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol. 2021;39(27):3056\u201382. https:\/\/doi.org\/10.1200\/JCO.21.00934.","journal-title":"J Clin Oncol."},{"key":"17041_CR10","unstructured":"Alliance for Clinical Trials in Oncology. A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy. clinicaltrials.gov; 2021. Accessed September 27, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01901094"},{"key":"17041_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS611","author":"WP Weber","year":"2024","unstructured":"Weber WP, Matrai Z, Hayoz S, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (OPBC-03\/SAKK 23\/16\/IBCSG 57\u201318\/ABCSG-53\/GBG-101-TAXIS). J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS611.","journal-title":"J Clin Oncol."},{"key":"17041_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.breast.2022.02.012","volume":"63","author":"A Matkin","year":"2022","unstructured":"Matkin A, Redwood J, Webb C, Temple-Oberle C. Exploring breast surgeons\u2019 reasons for women not undergoing immediate breast reconstruction. Breast. 2022;63:37\u201345. https:\/\/doi.org\/10.1016\/j.breast.2022.02.012.","journal-title":"Breast."},{"issue":"11","key":"17041_CR13","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1245\/s10434-020-08650-z","volume":"27","author":"G Montagna","year":"2020","unstructured":"Montagna G, Mamtani A, Knezevic A, Brogi E, Barrio AV, Morrow M. Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy. Ann Surg Oncol. 2020;27(11):4515\u201322. https:\/\/doi.org\/10.1245\/s10434-020-08650-z.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"17041_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","volume":"3","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy. JAMA Oncol. 2017;3(4):549\u201355. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4163.","journal-title":"JAMA Oncol."},{"issue":"11","key":"17041_CR15","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467\u201374. https:\/\/doi.org\/10.1245\/s10434-016-5246-8.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"17041_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778\u201385. https:\/\/doi.org\/10.1200\/JCO.2007.15.0235.","journal-title":"J Clin Oncol."},{"issue":"12","key":"17041_CR17","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","volume":"28","author":"M Untch","year":"2010","unstructured":"Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in her2-positive breast cancer: results from the GeparQuattro Study. J Clin Oncol. 2010;28(12):2024\u201331. https:\/\/doi.org\/10.1200\/JCO.2009.23.8451.","journal-title":"J Clin Oncol."},{"issue":"9","key":"17041_CR18","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med."},{"issue":"5","key":"17041_CR19","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1245\/s10434-015-4404-8","volume":"22","author":"P Cortazar","year":"2015","unstructured":"Cortazar P, Geyer CE. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol. 2015;22(5):1441\u20136. https:\/\/doi.org\/10.1245\/s10434-015-4404-8.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"17041_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1097\/PAS.0000000000001311","volume":"43","author":"A Grabenstetter","year":"2019","unstructured":"Grabenstetter A, Moo TA, Hajiyeva S, et al. Accuracy of intraoperative frozen section of sentinel lymph nodes after neoadjuvant chemotherapy for breast carcinoma. Am J Surg Pathol. 2019;43(10):1377\u201383. https:\/\/doi.org\/10.1097\/PAS.0000000000001311.","journal-title":"Am J Surg Pathol."},{"issue":"4","key":"17041_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1415340","volume":"373","author":"Timothy J Whelan","year":"2015","unstructured":"Whelan Timothy J, Olivotto Ivo A, Parulekar Wendy R, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1415340.","journal-title":"N Engl J Med."},{"issue":"8","key":"17041_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa020128","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567\u201375. https:\/\/doi.org\/10.1056\/NEJMoa020128.","journal-title":"N Engl J Med."},{"key":"17041_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS600","author":"EP Mamounas","year":"2019","unstructured":"Mamounas EP, Bandos H, White JR, et al. NRG Oncology\/NSABP B-51\/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC). J Clin Oncol. 2019. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS600.","journal-title":"J Clin Oncol."},{"issue":"4","key":"17041_CR24","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.3390\/curroncol30040306","volume":"30","author":"DB Lustig","year":"2023","unstructured":"Lustig DB, Temple-Oberle C, Bouchard-Fortier A, Quan ML. Incorporating lymphovenous anastomosis in clinically node-positive women receiving neoadjuvant chemotherapy: a shared decision-making model and nuanced approached to the axilla. Curr Oncol Tor Ont. 2023;30(4):4041\u201351. https:\/\/doi.org\/10.3390\/curroncol30040306.","journal-title":"Curr Oncol Tor Ont."},{"issue":"32","key":"17041_CR25","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","volume":"30","author":"EP Mamounas","year":"2012","unstructured":"Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30(32):3960\u20136. https:\/\/doi.org\/10.1200\/JCO.2011.40.8369.","journal-title":"J Clin Oncol."},{"issue":"2","key":"17041_CR26","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1245\/s10434-020-08928-2","volume":"28","author":"MF Almahariq","year":"2021","unstructured":"Almahariq MF, Levitin R, Quinn TJ, et al. Omission of axillary lymph node dissection is associated with inferior survival in breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy. Ann Surg Oncol. 2021;28(2):930\u201340. https:\/\/doi.org\/10.1245\/s10434-020-08928-2.","journal-title":"Ann Surg Oncol."},{"key":"17041_CR27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16143-6","author":"JN Limberg","year":"2024","unstructured":"Limberg JN, Jones T, Thomas SM, et al. Omission of axillary lymph node dissection in patients with residual nodal disease after neoadjuvant chemotherapy. Ann Surg Oncol. 2024. https:\/\/doi.org\/10.1245\/s10434-024-16143-6.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"17041_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.adro.2019.09.006","volume":"5","author":"DC Ling","year":"2020","unstructured":"Ling DC, Iarrobino NA, Champ CE, Soran A, Beriwal S. Regional recurrence rates with or without complete axillary dissection for breast cancer patients with node-positive disease on sentinel lymph node biopsy after neoadjuvant chemotherapy. Adv Radiat Oncol. 2020;5(2):163\u201370. https:\/\/doi.org\/10.1016\/j.adro.2019.09.006.","journal-title":"Adv Radiat Oncol."},{"issue":"3","key":"17041_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejso.2022.11.099","volume":"49","author":"Y Park","year":"2023","unstructured":"Park Y, Shin YS, Kim K, et al. Omission of axillary lymph node dissection in patients with ypN+ breast cancer after neoadjuvant chemotherapy: a retrospective multicenter study (KROG 21\u201306). Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2023;49(3):589\u201396. https:\/\/doi.org\/10.1016\/j.ejso.2022.11.099.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17041-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17041-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17041-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:14:28Z","timestamp":1746288868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17041-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["17041"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17041-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}